Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders

Tetsuya Akaishi, Tatsuro Misu, Toshiyuki Takahashi, Yoshiki Takai, Shuhei Nishiyama, Juichi Fujimori, Tadashi Ishii, Masashi Aoki, Kazuo Fujihara, Ichiro Nakashima

Research output: Contribution to journalArticlepeer-review

Abstract

The progression pattern of neurological disability among patients with anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) was evaluated. Neurological disability was evaluated annually for 408 person-years in 50 patients. More than 30% of the patients had clinical relapses in the first 5 years. Disability progression independent of relapse activity (PIRA) was not seen, whereas a stepwise disability progression was observed after clinical attacks in some instances. Disability worsening was more frequent after relapses than after the onset episode (p < 0.01). Similar to patients with anti-aquaporin-4 antibodies, attack-related stepwise disability progression without PIRA is typical in MOGAD, suggesting the importance of relapse prevention.

Original languageEnglish
Article number577467
JournalJournal of Neuroimmunology
Volume351
DOIs
Publication statusPublished - 2021 Feb 15

Keywords

  • Disability progression
  • MOG antibody-associated disorders
  • Myelin-oligodendrocyte glycoprotein (MOG)
  • Neuromyelitis optica spectrum disorders
  • Relapses

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Progression pattern of neurological disability with respect to clinical attacks in anti-MOG antibody-associated disorders'. Together they form a unique fingerprint.

Cite this